This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pluristem To Present At FDA Symposium

HAIFA, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has been invited to present at the U.S. Food & Drug Administration's (FDA) Medical Countermeasures initiative (MCMi) which is sponsoring its 2nd annual Regulatory Science Symposium on May 29-31, 2013 at FDA headquarters in Silver Spring, Maryland.

The FDA's Office of Counterterrorism and Emerging Threats, Medical Countermeasures Initiative, invited Pluristem to present at this symposium. William R. Prather RPh, MD, Pluristem's Senior Vice President Corporate Development, will present Pluristem's patented PLX (PLacental eXpanded) cell technology and its potential use in the treatment of the complications arising from the acute radiation syndrome (ARS). The data presented by Dr. Prather include preliminary preclinical information on the radio-mitigating activity of intramuscularly administered PLX-RAD cells generated in collaboration with Professor Raphael Gorodetsky and his team at the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center, Hadassit,Hadassah Medical Organization (HMO), Jerusalem, the National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, and the Berlin Bradenburg Center for Regenerative Therapies (BCRT), Charite University, Berlin.  

Zami Aberman, Pluristem's Chairman and CEO, stated, "We are proud to be invited to present data on the use of our PLX cells to mitigate the harmful effects sustained from acute radiation injury. This presentation is a supplement to the work currently being performed by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH), to evaluate our PLX cells in animal models of ARS."

  About Acute Radiation Syndrome (ARS)

ARS represents a constellation of signs and symptoms that occur between several minutes and several weeks after exposure to high doses of ionizing radiation and affecting multiple organs such as the hematological and gastrointestinal systems. The hematological syndrome follows radiation damage to the bone marrow and is characterized by severe decreases in red blood cells, white blood cells and platelets that predispose afflicted individuals to infection, bleeding and potential death.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs